Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's Pharmalittle newsletter.

Bristol Myers Squibb stock is holding in the mid-60 USD range after the company voluntarily paused e

Novartis suspended multiple studies of a CAR T candidate after three patients who received the therapy suffered fatal cases of immune effector cell-associated hemophagocytic syndrome. BMS, meanwhile, paused some CAR T trials after separately observing “transient and reversible inflammatory events"…

Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.

Quantitative Investment Management LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 67,290 shares of the biopharm

Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-five research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have assig

Wellington Management Group LLP decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,914,086 shares of the biopharmaceutical compan

Benjamin Edwards Inc. grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 14.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,873 shares of the biophar

Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychiatric diseases, with a “continuum of care” mindset.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,839,010 shares of t